13F Holdings
中文EN

RPRX Royalty Pharma plc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1802768 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY11.4%
TTM net income YoY-12.1%
TTM EPS YoY-12.6%
Revenue 3-yr CAGR4.0%
Net income 3-yr CAGR53.8%

Margins

Gross margin—
Operating margin57.1%
Net margin25.7%
FCF margin—
EBITDA margin57.3%

Returns

ROE10.1%
ROA3.5%
ROIC (approx.)10.2%
Asset turnover0.13x

Leverage & solvency

Liabilities / assets49.7%
Debt / equity1.26x
Current ratio1.29x
Interest coverage4.02x

Cash quality & payout

Operating cash flow / net income4.41x
Accruals ratio-11.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$2.38B$2.26B$2.35B$2.24B$2.29B
R&D expense$452.00M$2.00M$52.00M$177.11M$200.08M
SG&A expense$573.48M$236.67M$249.75M$227.30M$182.83M
Operating income$1.56B$1.29B$1.49B$307.06M$1.43B
Interest expense$307.66M$225.51M$187.19M$187.96M$166.14M
Pretax income$1.32B$1.33B$1.70B$230.06M$1.24B
Income tax$0$0$0$0$0
Net income$770.95M$858.98M$1.13B$42.83M$619.73M
EBITDA$1.56B$1.29B$1.49B——
EPS (basic)1.791.922.540.101.49
EPS (diluted)1.781.912.530.101.49
Dividends declared per share—0.840.800.760.68
Weighted avg. shares (diluted)564.46M594.11M602.90M437.97M414.80M
Banking
Provision for credit losses————$452.84M
Balance sheet
Cash & equivalents$618.70M$929.03M$477.01M$1.71B$1.54B
Short-term investments$18.80M$58.20M$18.30M$1.30M$66.00M
Current assets$1.53B$1.80B$1.27B$2.55B$2.88B
Goodwill$924.63M$0———
Intangibles———$0$5.67M
Total assets$19.62B$18.22B$16.38B$16.81B$17.52B
Current liabilities$636.21M$1.25B$161.38M$1.17B$171.25M
Short-term debt$380.00M$997.77M$0$997.51M$0
Long-term debt$8.57B$6.61B$6.14B$6.12B$7.10B
Total debt$8.95B$7.61B$6.14B$7.12B$7.10B
Total liabilities$9.91B$7.88B$6.30B$7.29B$7.27B
Shareholders' equity$6.48B$6.95B$6.53B$5.63B$5.78B
Net debt$8.33B$6.68B$5.66B$5.41B$5.56B
Cash flow statement
Operating cash flow$2.49B$2.77B$2.99B$2.14B$2.02B
Investing cash flow-$1.61B-$2.68B-$2.07B-$1.03B-$1.87B
Financing cash flow-$1.19B$361.14M-$2.15B-$944.86M$385.11M
Depreciation & amortization$3.85M$0$0——
Stock-based compensation$289.89M$2.34M$2.36M$2.17M$2.44M
Share buybacks$1.23B$229.65M$304.76M$0$0

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.